Analyst Ratings For Achaogen Inc (NASDAQ:AKAO)
Today, Mizuho reiterated its Hold rating on Achaogen Inc (NASDAQ:AKAO) with a price target of $8.00.
There are 7 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Achaogen Inc (NASDAQ:AKAO) is Buy with a consensus target price of $18.00 per share, a potential 450.46% upside.
Some recent analyst ratings include
- 11/6/2018-Achaogen Inc (NASDAQ:AKAO) had its Hold rating reiterated by Mizuho with a $8.00 price target
- 8/7/2018-Achaogen Inc (NASDAQ:AKAO) gets downgraded to Hold by Needham & Company LLC
- 7/27/2018-Achaogen Inc (NASDAQ:AKAO) had its Buy rating reiterated by Cowen
- 5/7/2018-Achaogen Inc (NASDAQ:AKAO) gets downgraded to Neutral by Guggenheim with a price target of $17.00
- On 9/25/2018 Blake Wise, COO, sold 3,242 with an average share price of $4.15 per share and the total transaction amounting to $13,454.30.
- On 9/25/2018 Gary Loeb, General Counsel, sold 1,038 with an average share price of $4.15 per share and the total transaction amounting to $4,307.70.
- On 6/26/2018 Blake Wise, CEO, sold 1,194 with an average share price of $9.59 per share and the total transaction amounting to $11,450.46.
- On 6/26/2018 Gary Loeb, General Counsel, sold 324 with an average share price of $9.59 per share and the total transaction amounting to $3,107.16.
- On 6/26/2018 Janet Dorling, Insider, sold 450 with an average share price of $9.59 per share and the total transaction amounting to $4,315.50.
- On 6/26/2018 Tobin Schilke, CFO, sold 298 with an average share price of $9.59 per share and the total transaction amounting to $2,857.82.
- On 6/11/2018 Tobin Schilke, CFO, sold 2,087 with an average share price of $11.95 per share and the total transaction amounting to $24,939.65.
About Achaogen Inc (NASDAQ:AKAO)
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Recent Trading Activity for Achaogen Inc (NASDAQ:AKAO)
Shares of Achaogen Inc closed the previous trading session at 3,27 −0,47 12,57 % with 3.24 shares trading hands.
